Abstract: A transdermal psychoactive alkaloid composition including a psychoactive alkaloid extract or synthetic psychoactive alkaloid. The alkaloids in the extract are predominantly dephosphorylated rather than phosphorylated. The transdermal psychoactive alkaloid composition also includes an alcohol carrier, a permeation enhancer, a thickener or gelling agent, and optional further excipients. A process for obtaining a transdermal psychoactive alkaloid composition includes dephosphorylating the alkaloid during extraction, purifying the extracted alkaloid, and standardizing it to a specific concentration by adding measured quantities of excipients.

Abstract: A nutritional and cosmetic system, product, and method for improving the health, growth and appearance of hair, skin, nails, and body, including the principle active ingredients of lipids and vitamins, including vitamin C, and biotin and minerals, including phosphorus, wherein the product is applied topically to the skin, hair, nails and, or body while also being ingested and, or injected. A vanilla or other scented extract may be added to enhance the pleasant scent of the product and system. The nutritional and cosmetic product and system may be applied to the hair directly or in a shampoo, to the face, body, and nails, ingested, and or applied topically to the hair, skin, nails and or body.

Abstract: The device is intended for the noninvasive induction of dynamic deformation of body tissue to differentiate tissue cells. It comprises the following components: (i) a suspension of particles suspended in solution; and (ii) an external actuator which is capable of magnetically, electrically, vibrationally, or thermally stimulating the suspended particles.

Abstract: Balloon catheters, methods for preparing balloon catheters, and uses of balloon catheters are disclosed. The balloon catheter includes an elongate member, an expandable balloon, and a coating layer overlying an exterior surface of the expandable balloon. The coating layer includes a total drug load of a hydrophobic therapeutic agent and a combination of additives including a first additive and a second additive. The hydrophobic therapeutic agent is paclitaxel, rapamycin, or paclitaxel and rapamycin. The first additive is a surfactant. The second additive is a chemical compound having one or more hydroxyl, amino, carbonyl, carboxyl, acid, amide, or ester groups.

Abstract: The present invention relates to a modified-release composition comprising orlistat and acarbose, comprising individually distinct parts with different release patterns: a) a first part, G1, comprising from about 5 to about 70% w/w of the total dose of acarbose, b) a second part, G2A, comprising from about 30 to about 95% w/w of the total dose of acarbose, c) a third part, G2B, comprising from about 10 to about 90% w/w of the total dose of orlistat, and d) a fourth part, G3, comprising from about 10 to about 80% w/w of the total dose of orlistat, and the total concentration of acarbose and orlistat, respectively, in the composition is 100% w/w.

Abstract: A 9-(5-bromo-2-hydroxyphenyl)-10-[3-(dimethylamino)propyl]-3,4,6,7,9,10-hexahydroacridine-1,8(2H,5H)-dione compound, its synthesis, and its use as an antimicrobial agent.

Abstract: A 9-(5-bromo-2-hydroxyphenyl)-10-[3-(dimethylamino)propyl]-3,4,6,7,9,10-hexahydroacridine-1,8(2H,5H)-dione compound, its synthesis, and its use as an antimicrobial agent.

Abstract: The present invention relates to a pediatric powder for reconstitution as suspension for oral administration comprising a therapeutically effective amount of an antiviral agent or pharmaceutical acceptable salt or derivative thereof, in particular Valaciclovir in complex with an ion exchange resin in a specific ratio in order to obtain a palatable and child-friendly product. It also relates to a process for the preparation thereof.

Abstract: The non-therapeutic, cosmetic, oral use of a composition as an active ingredient for whitening and/or lightening the skin and/or depigmenting the skin, in particular for reducing the size of brown spots, including at least cystine and glutathione in a cystine/glutathione ratio ranging from 1.5 to 4, the composition advantageously further comprising glycine and/or glutamine Preferably, the composition also includes at least one component selected from the group formed by zinc or one of its salts, copper or one of its salts, selenium or one of its salts, vitamins B, in particular B3, B5, B6 and/or B8, vitamin E, melon juice extracts, horsetail extracts and mixtures of these components.

Abstract: A pharmaceutical composition is described which includes diclofenac as an active ingredient. The pharmaceutical composition further includes a (meth)acrylic polymer which has a specific solubility and/or a particular functional group in one polymer component.

Abstract: A process is described for the preparation of a hair treatment composition, which comprises the following process steps: a) Providing a water phase (Ia) comprising water and optionally other components and heating the water phase to a temperature of from about 70 to about 95° C., b) Providing an oil phase (Ib) comprising at least one oil and at least one emulsifier, and adding the oil phase to the heated water phase from step a), c) Homogenize the mixture from step b), d) Cooling the emulsion resulting from step c) to a temperature of from about 35 to about 45° C. and optionally adding further active ingredients, e) Filling of the emulsion resulting from step d) into preferably transparent containers, whereby in the resting state after from about 10 to about 90 minutes a separation into a water phase (II) and an emulsion phase (IIb) occurs.

Abstract: The present invention relates to topical compositions comprising at least one polar oil and a micronized 1,4-di(benzoxazol-2?-yl)benzene having a mean particle size of at most 300 nm as well as to the use of such a micronized 1,4-di(benzoxazol-2?-yl)benzene to reduce the transfer of such oils to surfaces.

Abstract: The present invention relates to a composition of a calcium phosphate such as tetracalcium phosphate or ?-TCP and an additive compound selected from nucleic acid or nucleotides, phospho(enol)pyruvic acid and phosphocreatine. The composition may be used as a tissue adhesive.

Abstract: Provided are aromatic oligoamide foldamers and self-assembled compositions of the same. The aromatic oligoamide foldamers and compositions can form tube-like structures that can form pores in membranes. The pores can be used to transport ions and molecules, such as, for example, cryoprotective agents or therapeutic agents, through the membrane. The tube-like structures exhibit desirable stability at low temperatures.

Abstract: The present disclosure provides for suspension-based pharmaceutical formulations for cold and flu medications, specifically suspension formulations and soft gel capsule dosage forms having reduced size. The present disclosure also provides methods of preparing the suspensions and soft gel capsule dosage forms.

Abstract: Provided herein is a method of preparing a ceramic material, the method including: providing a ceramic gel including a plurality of metal salts and compressing the ceramic gel thereby inducing stress-induced mineralization of the ceramic gel and formation of the ceramic material, wherein the ceramic gel exists in isolated form.

Abstract: A method for depositing a coating comprising a polymer and pharmaceutical agent on a substrate, comprising the following steps: discharging at least one pharmaceutical agent in a therapeutically desirable morphology in dry powder form through a first orifice; discharging at least one polymer in dry powder form through a second orifice; depositing the polymer and/or pharmaceutical particles onto said substrate, wherein an electrical potential is maintained between the substrate and the pharmaceutical and/or polymer particles, thereby forming said coating; and sintering said coating under conditions that do not substantially modify the morphology of said pharmaceutical agent.

Abstract: The present invention is related to novel compositions comprising at least one active ingredient of the family of the triazines combined with another active ingredient and specific compounds that allow the reduction of foam formation. More particularly, the invention relates to compositions in the form of aqueous suspensions comprising a triazine, an iron complex, and one or more surfactant(s) having a particular HLB.

Abstract: The present invention is related to novel compositions comprising at least one active ingredient of the family of the triazines combined with another active ingredient and specific compounds that allow the reduction of foam formation. More particularly, the invention relates to compositions in the form of aqueous suspensions comprising a triazine, an iron complex, and one or more surfactant(s) having a particular HLB.

Abstract: The present invention is related to novel compositions comprising at least one active ingredient of the family of the triazines combined with another active ingredient and specific compounds that allow the reduction of foam formation. More particularly, the invention relates to compositions in the form of aqueous suspensions comprising a triazine, an iron complex, and one or more surfactant(s) having a particular HLB.